· Published by Health Canada · Official notice
This is duplicated text of a letter from Eli Lilly Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 06, 2005
Subject: Association of Xigris® with Intracranial Hemorrhage in Pediatric Patients and Discontinuation of Study F1K-MC-EVBP (Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis) based on failure to reach desired clinical endpoints and an unfavourable benefit/risk profile.
Dear Health Care Professional,
Eli Lilly Canada Inc., following discussions with Health Canada, would like to inform you of important safety information regarding Xigris [drotrecogin alfa (activated), recombinant human activated Protein C, rhAPC]. Xigris is indicated for the treatment of adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (e.g. as determined by APACHE II score or multiple organ dysfunctions).
Based on the recommendation of the Data Monitoring Committee (DMC), Eli Lilly and Company recently stopped enrollment in study EVBP, a randomized, double-blind, placebo-controlled trial of Xigris [drotrecogin alfa (activated)] in pediatric patients with severe sepsis. Xigris is not indicated for use in pediatric severe sepsis.
The DMC also noted a numerical increase in the rate of intracranial hemorrhage (ICH) in the Xigris versus the placebo group. Over the infusion period (study days 0-6) the number of patients experiencing an event was 4 versus 1 for the overall population (Xigris vs. placebo), with 3 of the 4 events in the Xigris group occurring in patients aged 60 days or less (median age of patients enrolled was 2.3 years). Mortality, the rate of serious adverse events, overall serious bleeding events, and major amputations appeared to be similar in the Xigris and placebo groups.
The main findings of the interim analysis are summarized in the following table:
|
Xigris N=201 n (%) |
Placebo N=198 n(%) |
|
|---|---|---|
|
Table 1 footnotes
|
||
| CTCOFRS (Composite Time to Complete Organ Failure Resolution), mean score standard deviation | 9.7 + 5.0 | 9.8 + 5.1 |
|
28-day all-cause mortality Deaths attributable to hemorrhage by investigatorTable 1 footnote * |
34 (16.9) 1 (0.5) |
36 (18.2) 5 (2.5) |
|
Intracranial hemorrhage (ICH) Days 0-6 (infusion period) Days 0-28 (entire study period) |
4 (2.0) 8 (4.0) |
1 (0.5) 5 (2.5) |
|
Serious Adverse Events Days 0-6 (infusion period) Days 0-28 (entire study period) |
21 (10.4) 35 (17.4) |
23 (11.6) 40 (20.2) |
|
Serious Bleeding Events Days 0-6 (infusion period) Days 0-28 (entire study period) |
8 (4.0) 13 (6.5) |
7 (3.5) 14 (7.1) |
| At least one ICH event OR died during 28-day study period. | 39 (19.4) | 38 (19.2) |
| Major Amputations | 4 (2.0) | 6 (3.0) |
Data collection in study EVBP is ongoing. All patients enrolled will be followed for the complete 28-day study period. Full results of the complete dataset will be available in the latter half of 2005 and publicly presented as soon as possible.
This Dear Healthcare Professional Letter is posted on both the Eli Lilly Canada web site and the Health Canada web site.
The identification, characterization and management of marketed health product-related adverse reactions are dependent on the active participation of healthcare professionals in adverse reaction reporting programmes. You can assist us with monitoring the safety of Xigris by reporting adverse events to Eli Lilly Canada Inc. or Health Canada at the following addresses:
Customer Response Centre
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, ON M1N 2E8
Toll Free Number: 1-888-545-5972
Fax: 1-888-898-2961
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 1 866 234-2345
Fax: 1 866 678-6789
Email: cadrmp@hc-sc.gc.ca
For other inquiries, please refer to contact information:
Marketed Health Products Directorate
Email: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
Lilly is committed to providing you with the most up-to-date and accurate information regarding its products. Inquiries from healthcare professionals should be directed to Eli Lilly Canada Customer Response Centre at 1-888-545-5972 between 8 a.m. and 6 p.m. EST.
original signed by
Loren D. Grossman, MD, FRCPC, FACP
Vice President, Research and Development
Eli Lilly Canada Inc.
® Registered trademark owned by Eli Lilly and Company; used under license.